Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract...
Oculis Holding AG (OCS)
Company Research
Source: GlobeNewswire
OCS-01 positive results in the first Phase 3 OPTIMIZE-1 trial were presented at the American Society of Cataract and Refractive Surgery (ASCRS) while topline readout from the second Phase 3 OPTIMIZE-2 is anticipated later this year to support NDA submissionIf approved, OCS-01 would be the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery OCS-01 is also in Phase 3 development as potentially the first eye drop treatment for Diabetic Macular Edema (DME) ZUG, Switzerland and BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Eric Donnenfeld, M.D., presented the positive results from the Phase 3 OPTIMIZE-1 trial of OCS-01 for the treatment of inflammation and pain following cataract surgery at the 2024 ASCRS Annual Meeting, which took place April 5-8, 2024
Show less
Read more
Impact Snapshot
Event Time:
OCS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCS alerts
High impacting Oculis Holding AG news events
Weekly update
A roundup of the hottest topics
OCS
News
- Oculis Publishes Invitation to the Annual General MeetingGlobeNewswire
- Oculis Holding AG (NASDAQ: OCS) had its price target lowered by analysts at HC Wainwright from $29.00 to $28.00. They now have a "buy" rating on the stock.MarketBeat
- Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main MarketGlobeNewswire
- Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market [Yahoo! Finance]Yahoo! Finance
- Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market [Yahoo! Finance]Yahoo! Finance
OCS
Sec Filings
- 4/29/24 - Form 6-K
- 4/22/24 - Form 6-K
- 4/11/24 - Form 424B5
- OCS's page on the SEC website